Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

DCPrime Appoints CEO and CMO and Expands Supervisory Board

Published: Tuesday, October 09, 2012
Last Updated: Tuesday, October 09, 2012
Bookmark and Share
Company appoints Marcel Zwaal and Dr. Anthony Hall as CEO and CMO respectively.

Cancer vaccine company DCPrime has announced the appointments of Marcel Zwaal as Chief Executive Officer, and of Dr. Anthony Hall as Chief Medical Officer.

Dr. Anthony Hall has 18 years of experience in clinical drug development, in particular in orphan drug indications.

Dr. Ada Kruisbeek, founder of DCPrime and since the start of the company active in a dual role as CEO and Chief Scientific Officer, will continue to build and expand the company’s product platform technology as CSO.

“DCPrime is entering a new stage of its development with an on-going Phase I/IIa trial in Acute Myeloid Leukemia and a Phase II efficacy trial to start in the course of 2013,” said Michel Briejer, Chairman of DCPrime’s Supervisory Board.

Briejer continued, “With Marcel stepping up from Chief Business Officer to the position of CEO, Ada focusing on reinforcing and expanding the platform, and Tony joining to move our clinical programs forward, DCPrime has a formidable team in place to bring the company’s exciting new class of off-the-shelf cancer vaccines to market.”

DCPrime also appointed Bart Klein to its Supervisory Board. Mr. Klein, former Executive Vice President Intellectual Property & Legal Affairs at Crucell, brings 23 years of experience in intellectual property and licensing.

In addition to Mr. Klein, the Supervisory Board consists of Onno van de Stolpe, CEO of Galapagos, Dr. Herbert Heyneker, one of the most distinguished scientist entrepreneurs in the biotech industry, Dr. Leon Hooftman who, following a high-profile career in clinical development, currently is Chief Medical Officer of Synthon, and Dr. Michel Briejer, chairman and partner of Thuja Capital, DCPrime’s cornerstone investor.

“I am delighted to take the helm from Ada, and be given the opportunity to lead the charge to bring DCPrime’s cancer vaccines to patients with real unmet medical needs,” said Marcel Zwaal, CEO.

Zwaal continued, “Supported by our dedicated board members, our management team now has all the capabilities to make a push forward, and capitalize on our first-in-class product platform to develop effective cancer vaccines.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

European Medicines Agency Approves Orphan Medicinal Product Application of DCPrime's AML Vaccine
DCPrime's AML vaccine has potential to improve the survival of patients with leukemia.
Thursday, February 02, 2012
Scientific News
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
Dormant Viral Genes May Awaken to Cause ALS
NIH human and mouse study may open an unexplored path for finding treatments.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Five Genetic Regions Implicated In Cystic Fibrosis Severity
An international consortium of researchers conducted the largest-ever CF genome-wide analysis to find new therapeutic targets.
Greater Understanding Of Polycystic Ovary Syndrome
A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
New Autism Genes Are Revealed in Largest-Ever Study
Work draws more detailed picture of genetic risk, sheds light on sex differences in diagnosis.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Genetic Adaptations to Diet and Climate
Researchers found genetic variations in the Inuit of Greenland that reflect adaptations to their specific diet and climate.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos